CFN Media Group, the major digital media and creative agency network committed to legal cannabis, reported the issue of an article and interview with OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) CSO Dr. Yehuda Baruch. The interview emphases on Dr. Baruch’s remarkable background in cannabis research, the firm’s clinical trial plan, and the general prospects for cannabis as a drug.
OWC Pharmaceutical owns 100% of its subsidiary unit One World Cannabis Ltd. The latter was established to lay pharmaceutical research protocols as well as disciplines to the international medical cannabis market. Dr. Baruch spearheads the firm’s research measures after being the head of the Medical Cannabis Program for more than 10 years, managing regulatory compliance, clinical trials and other industry-wide problems.
OWC Pharmaceuticals is concentrated on the advancement of two delivery plans: A proprietary, CBD-enriched sublingual tablet and an exclusive topical compound. Besides these, the firm intends to address numerous multi-billion-dollar end industries counting grave medical ailments such as multiple myeloma, fibromyalgia, psoriasis and post-traumatic stress disorder, along with hundreds of increased addressable indications in the coming period.
OWC Pharmaceuticals reported the advancement of a proprietary, CBD-enriched sublingual tablet for medical cannabis in the last October. The tablet was advanced to surge the bioavailability of CBDs and offer an optimal administration process for consistent dosing. OWC Pharmaceuticals intends to advance the tablet to cure conditions like post-traumatic stress disorder, fibromyalgia and multiple myeloma.
Prior to releasing the tablet, the firm closed in-vitro testing of a CBD-based offering for multiple myeloma in March 2016. The company’s management intends to proceed with pre-clinical studies approved by the IRB to duplicate that outcome in mice before progressing with human studies. The in-vitro testing demonstrated 100% malignant cell death in as much as 60% of diseased mice cells, promising report.
OWC Pharmaceuticals produced a topical CBD-based cream for the cure of psoriasis in association with one of Israel’s leading cosmetic manufacturers, Emilia Cosmetics Ltd. in March 2016.